Private Advisor Group LLC Purchases New Position in Novavax, Inc. (NASDAQ:NVAX)

Private Advisor Group LLC acquired a new stake in shares of Novavax, Inc. (NASDAQ:NVAXFree Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,160 shares of the biopharmaceutical company’s stock, valued at approximately $81,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in NVAX. Geneos Wealth Management Inc. raised its position in Novavax by 124.7% in the first quarter. Geneos Wealth Management Inc. now owns 1,809 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 1,004 shares during the period. US Bancorp DE raised its position in Novavax by 41.8% in the first quarter. US Bancorp DE now owns 2,083 shares of the biopharmaceutical company’s stock worth $154,000 after acquiring an additional 614 shares during the period. Neuberger Berman Group LLC raised its position in Novavax by 34.9% in the first quarter. Neuberger Berman Group LLC now owns 2,764 shares of the biopharmaceutical company’s stock worth $204,000 after acquiring an additional 715 shares during the period. Toroso Investments LLC raised its position in Novavax by 15.3% in the first quarter. Toroso Investments LLC now owns 3,297 shares of the biopharmaceutical company’s stock worth $243,000 after acquiring an additional 437 shares during the period. Finally, PDT Partners LLC bought a new position in Novavax in the first quarter worth approximately $243,000. Institutional investors own 71.46% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded shares of Novavax from a “sell” rating to a “hold” rating in a research report on Friday, December 8th.

Read Our Latest Research Report on NVAX

Novavax Price Performance

Shares of NASDAQ NVAX opened at $3.78 on Thursday. The firm has a fifty day moving average price of $4.78 and a 200-day moving average price of $6.39. The stock has a market cap of $449.03 million, a PE ratio of -0.59 and a beta of 1.47. Novavax, Inc. has a 1 year low of $3.53 and a 1 year high of $11.36.

Novavax (NASDAQ:NVAXGet Free Report) last announced its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.82) by $0.56. The firm had revenue of $187.00 million during the quarter, compared to analysts’ expectations of $171.04 million. The business’s revenue for the quarter was down 74.5% on a year-over-year basis. During the same period last year, the company earned ($2.15) earnings per share. On average, research analysts expect that Novavax, Inc. will post -3.87 EPS for the current year.

Novavax Profile

(Free Report)

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.

Featured Stories

Want to see what other hedge funds are holding NVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novavax, Inc. (NASDAQ:NVAXFree Report).

Institutional Ownership by Quarter for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.